

# JRC TECHNICAL REPORT

## Determination of MOAH in Infant Formula

JRC IF 2020-01 - an exploratory interlaboratory comparison

Bratinova S., Robouch P.

Karasek L., Goncalves C., Beldi G., Senaldi C., Jakubowska N., Valzacchi S. Conneely P.

Hoekstra E., Emons H.



Joint Research Centre This publication is a Technical report by the Joint Research Centre (JRC), the European Commission's science and knowledge service. It aims to provide evidence-based scientific support to the European policymaking process. The scientific output expressed does not imply a policy position of the European Commission. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use that might be made of this publication. For information on the methodology and quality underlying the data used in this publication for which the source is neither Eurostat nor other Commission services, users should contact the referenced source. The designations employed and the presentation of material on the maps do not imply the expression of any opinion whatsoever on the part of the European Union concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Contact information Name: Stefanka Bratinova Address: European Commission Joint Research Centre (JRC) Retieseweg 111 Geel 2440, Belgium Email: Stefanka-Petkova.BRATINOVA@ec.europa.eu Tel.: 0032 14 571800 EU Science Hub https://ec.europa.eu/jrc

JRC 121915 EN

Geel: European Commission, 2020

© European Union, 2020



The reuse policy of the European Commission is implemented by the Commission Decision 2011/833/EU of 12 December 2011 on the reuse of Commission documents (OJ L 330, 14.12.2011, p. 39). Except otherwise noted, the reuse of this document is authorised under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence (<u>https://creativecommons.org/licenses/by/4.0/</u>). This means that reuse is allowed provided appropriate credit is given and any changes are indicated. For any use or reproduction of photos or other material that is not owned by the EU, permission must be sought directly from the copyright holders.

All content © European Union, 2020

How to cite this report: Bratinova S., Robouch P., Karasek L., Goncalves C., Beldi G., Senaldi C., Jakubowska N., Valzacchi S., Conneely P., Hoekstra E., Emons H. *Determination of MOAH in Infant Formula, JRC IF 2020-01 - an exploratory interlaboratory comparison*, European Commission, Geel, 2020, JRC 121915

## **Table of Contents**

Ex	Executive summary		1
1	1 Introduction		2
2	2 Scope		2
3	3 Set-up of the exercise		2
4	4 Results and Discussions		4
	4.1 Results		4
	4.2 Questionnaire		6
	4.3 Details about the experimental procedures	used	6
	4.4 Limit of quantification		9
	4.5 Laboratory experience		11
5	5 Conclusions		12
Ac	Acknowledgements		13
	Annex 1: Invitation letter		14
	Annex 2: Instructions to participants		15
	Annex 3: Confirmation of receipt form		17
	Annex 4. Eusurvey – online questionnaire		18
	Annex 5. Results as reported by the participants	s for total MOAH in IF (in mg kg $^{-1}$ )	32
	Annex 6. Results as reported by the participants	s for the MOAH C35-C50 fraction in IF (in mg kg $^{-1}$ )	33
	Annex 7. Results as reported by the participants	s for the MOAH C25-C35 fraction in IF (in mg kg^-1)	34
	Annex 8. Results as reported by the participants	s for the MOAH C16-C25 fraction in IF (in mg kg $^{-1}$ )	35
	Annex 9. Results as reported by the participants	s for the MOAH C10-C16 fraction in IF (in mg kg $^{-1}$ )	36

#### **Executive summary**

An exploratory interlaboratory comparison (ILC) was organised by the Joint Research Centre (JRC) in the frame of developing on request of DG SANTE a harmonised method for the determination of mineral oil aromatic hydrocarbons (MOAH) in infant formula (IF). This report presents the outcome of the ILC called JRC IF 2020-01 and attended by 27 participants from 8 European countries.

A thorough questionnaire related to the employed experimental details was elaborated by the organisers and filled in by the participants. The results reported were used to identify the best experimental practices in view of selecting the best analytical approach. This study should further advance the harmonisation of a standard operating procedure which will be in a next step validated using a ring-trial.

## 1 Introduction

Following the RASFF notification message 2019.3734 (dated 25/10/2019) [1] and the Foodwatch findings [2] related to mineral oil aromatic hydrocarbons (MOAH) in infant formula and follow-on formula (IF), the Directorate General for Health and Food Safety (DG SANTE) of the European Commission requested the Joint Research Centre (JRC) to organise a Roundtable Workshop on the determination of MOAH in IF [3]. The meeting held in Brussels on December 5, 2019, was attended by various stakeholders (e.g. official control laboratories, industry and NGOS), DG SANTE and EFSA. The comparability and reliability of the analytical procedures applied by laboratories to monitor the MOAH content in IF was thoroughly discussed. A broad variety of experimental procedures were reviewed. Participants agreed to simplify the experimental protocols and identified the need for a harmonised method to be validated and further standardised.

JRC committed (i) to coordinate the work; (ii) to collect the available standard operating procedures used by the experienced laboratories; (iii) to draft a harmonised SOP to be reviewed; and (iv) to organise a ring-trial exercise for the validation of the harmonised protocol. Hence, the JRC decided to organise an exploratory interlaboratory comparison (ILC) to evaluate the analytical procedures applied to determine the MOAH mass fraction in an infant formula sample. This report represents the outcome of the ILC **JRC IF 2020-01**.

## 2 Scope

JRC IF 2020-01 aimed to collect and evaluate the different SOPs applied by a variety of participants (official control laboratories, industry, NGOs and universities) when analysing the MOAH content in a well characterised infant formula test item. Successful/satisfactory results will be used to identify the reliability and robustness of experimental steps to be used, thus resulting in a detailed SOP to be further investigated.

## **3** Set-up of the exercise

In February 2020, the JRC identified and purchased at a local supermarket three 800 g cans (displaying the same batch number) of a commercial IF powder with a suitable MOAH content for the interlaboratory comparison. The material was mixed, homogenised and bottled (25 g aliquots in 100 ml brown glass bottles) by the JRC. All necessary measures were taken to prevent cross-contaminations:

- the bottles were baked before filling at 400 °C for at least 6 h;
- the crimp cap used for closure contained Teflon lining; and
- an aluminium (Al) foil was inserted between the caps and the bottle neck. In addition, the bottles were wrapped in Al foil to prevent any potential gas-phase cross contaminations during the shipment and storage.

Due to the imposed COVID-19 lockdown in Belgium, the homogeneity study could not be finalised. However, the thorough mixing of the content of three cans of the commercial powder IF, originating from the same batch, is assumed as sufficient to produce homogeneous test items.

<sup>(1)</sup> https://www.foodwatch.org/fileadmin/-DE/Themen/Mineraloel/Dokumente/Mineraloel RASFF\_BVL\_30-03-2020.pdf

<sup>(2) &</sup>lt;u>https://www.foodwatch.org/en/news/2019/foodwatch-laboratory-tests-suspected-carcinogenic-mineral-oil-residues-in-baby-milk/</u>

<sup>(3)</sup> Report from the Roundtable meeting: <u>https://ec.europa.eu/jrc/en/eurl/food-contact-materials/technical-guidelines</u>

## **Confidentiality**

The procedures used for the organisation of ILCs guarantee that the identity of the participants and the information provided by them is treated as confidential. The participants in this ILC received a unique laboratory code used throughout this report.

#### <u>Time frame</u>

JRC IF 2020-01 was announced by email on February 13, 2020 (Annex 1, Invitation letter). Due to the upcoming COVID-19 pandemic, with a lockdown expected to be implemented shortly in Belgium, a strict deadline for registration was set to March 17, 2020 - 09:00 h. On that day, all samples were dispatched to participants. At first a tentative deadline for reporting of results was set to May 10, 2020. It was first extended to end of May, due to the ongoing COVID-19 pandemics, with the last reported results accepted on June 18, 2020.

#### **Distribution**

Each participant received:

- One bottle containing 25 g of powder IF in a 100 ml brown glass bottle;
- The "Instruction to participants" (Annex 2); and
- The "Confirmation of receipt form" to be sent back to the PT coordinator after receipt of the test item (Annex 3).

#### Instructions to participants

Detailed instructions were provided to the participants by e-mail (Annex 2). They were requested to apply experimental protocols complying with (i) the decisions taken during the Roundtable meeting and (ii) the requirements set in the "EURL-FCM Guidance on sampling, analysis and data reporting" [4].

The following measurands were defined:

- "the mass fraction of total MOAH in IF", expressed in mg kg<sup>-1</sup>
- "the mass fraction of the MOAH in IF corresponding to the retention time of n-alkanes from n-C35 to n-C50 (MOAH C35-C50)", expressed in mg kg<sup>-1</sup>
- \* "the mass fraction of the MOAH in IF corresponding to the retention time of n-alkanes from n-C25 to n-C35 (MOAH C25-C35)", expressed in mg kg<sup>-1</sup>
- ""the mass fraction of the MOAH in IF corresponding to the retention time of n-alkanes from n-C16 to n-C25 (MOAH C16-C25)", expressed in mg kg<sup>-1</sup>
- \* "the mass fraction of the MOAH in IF corresponding to the retention time of n-alkanes from n-C10 to n-C16 (MOAH C10-C16)", expressed in mg kg<sup>-1</sup>

Participants were asked to check whether the test items were undamaged after transport and to report, if necessary, using the "Confirmation of receipt form" (Annex 3).

In addition, participants were requested to:


• Perform three independent measurements;

<sup>(4)</sup> JRC Report – Guidance on sampling, analysis and data reporting for the monitoring of mineral oil hydrocarbons in food and food contact materials (EUR-29666, 2019) <a href="https://europa.eu/!nx87Th">https://europa.eu/!nx87Th</a>

- Report their calculated mean (in mg kg<sup>-1</sup>), derived from their replicates as they would report to their customer;
- Provide the associated expanded uncertainty (in mg kg<sup>-1</sup>), specifying the coverage factor;
- Fill the experimental details into the online questionnaire [5] (Annex 4) about the applied method; and
- Provide the recorded chromatograms.

## 4 Results and Discussions

A total of 30 laboratories registered to the JRC IF 2020-01 round. Twenty-seven participants from 8 EU countries reported results; of which 26 filled in the detailed online questionnaire related to their standard operation procedure (SOP) and 25 provided the requested chromatograms.



#### 4.1 Results

This exploratory interlaboratory comparison aimed to evaluate the analytical procedures used when monitoring MOAH in IF. This will allow the identification of the relevant experimental steps to be included in the harmonised/standard analytical method for further validation.

JRC IF 2020-01 was not intended as a proficiency testing exercise, hence no reported results were scored. In addition, the "assigned values" that could have been obtained applying robust statistics are not considered as reliable estimates of the "true values".


Participants reported quantitative results (numerical values) for total MOAH (Annex 5) and the C25-C35, C35-C50 fractions (Annexes 6-7). "Less values" were mainly reported for the C10-C16 and C16-C25 fractions (Annexes 7-8). The reported results together with their associated expanded uncertainties are presented graphically in Figure 1.

Based on the kernel distribution presented in Figure 2, the reported total MOAH mass fractions ranging from 2.2 to 3.7 mg kg<sup>-1</sup> (bracketing the main mode at 3.0 mg kg<sup>-1</sup>) are considered suitable for the identification of proper analytical steps and experimental procedures. Results below 1.4 mg kg<sup>-1</sup> or above 4.2 mg kg<sup>-1</sup> seem to be unsatisfactory.

While the JRC Guidance document [4] recommends to integrate the entire chromatogram when determining the total MOAH content, many participants reported the total MOAH as sum of the content of the different (quantified) fractions, applying a lower bound approach. Such an approach would provide underestimated results, when MOAH is detected but not quantified in some of the fractions.

<sup>(5) &</sup>lt;u>https://ec.europa.eu/eusurvey/runner/JRC\_IF\_2020\_01A</u>

Participants (with experience or novel in the field) displayed a broad range for the relative intermediate precision parameter (up to 60 %) at LOQ levels. This should be significantly improved in order to comply with the 25 % limit required by the JRC Guidelines for official controls.



**Figure 1** Distribution of the results from the participants in JRC IF 2020-01; a) total MOAH; b) MOAH C35-C50; c) MOAH C25-C35




Figure 2 Kernel density plot and Kernel density mode for total MOAH results

## 4.2 Questionnaire

The structure of the online questionnaire (Annex 4, [5]) was based on the main experimental steps (listed hereafter) that were identified and discussed during the Roundtable meeting:

- □ Saponification;
- □ Extraction;
- Epoxidation;
- □ Column clean-up;
- □ On-line or off-line LC-GC MOSH/MOAH separation; and
- □ FID chromatogram quantification.

#### 4.3 Details about the experimental procedures used

Important conclusions about the good practices and critical steps requiring further investigations were derived from the experimental details provided by the laboratories in the questionnaire:

- ✓ Satisfactory total MOAH mass fractions were reported by laboratories having applied the experimental pathways A, B, C, D and E (Figure 3);
- ✓ Largely scattered (and often unsatisfactory) results were reported when proceeding without reconstitution of the powdered IF (G and H). This supports the Roundtable decision recommending the reconstitution of the powder IF before further steps.

At that time, questions were raised by the organisers whether the different experimental pathways chosen by laboratories (e.g. saponification and extraction) would significantly influence the measurement results. After experimental comparison of the A-D approaches and experts' consultations, the use of hot water reconstitution of the IF, followed by saponification and extraction was chosen to be the most effective procedure.

The following important observations concerning the experimental steps were made:

- ✓ Approximately 2 g KOH (from 1.5 to 2.5 g) were used for the saponification of a 5 g sample intake, performed at 60 to 80 °C for 30 to 120 min, using different mixing/shaking approaches (see Figure 4).
- Although the Roundtable recommended the use of an ethanolic KOH saturated solution for saponification, satisfactory results (12 out of 18) were also obtained when using a 50 % water solution of KOH, which is more favourable for handling.
- ✓ Applying saponification in the organic phase only after extraction (E) does not comply with the Roundtable decisions. Despite the good results reported by two participants, this approach may not be applicable to all kinds of IF and should not be recommended at this point.
- ✓ Epoxidation and additional clean-up are the most critical steps. They have to be applied with due care and must be assessed for their effectiveness and robustness. Despite the Roundtable requirement of implementing the so-called *Nestola procedure* (including epoxidation in ethanolic media) [6], two participants successfully applied a different protocol and performed epoxidation at sub-ambient temperature in DCM.
- Most of the participants used 100 to 200 mg chlorobenzoic acid (mCPBA) for epoxidation. Only 5 laboratories reported preliminary purification of the acid by washing with hexane. Consequently, purification should be performed (if needed), depending on the purity of each new batch of the reagent. The mCPBA amount depends on whether there is a column cleanup step before the epoxidation.




Figure 3. Influence of the experimental path chosen for the results of the ring trial

<sup>&</sup>lt;sup>6</sup> Nestola M., M., Schmidt T. Journal of Chromatography A, 1505 (2017) 69–76





Figure 4. Different way of insuring phase contact during the saponification step



**Figure 5** Type of the stop reagent for the reaction of epoxidation

- ✓ Half (8/17) of the laboratories used only sodium thiosulfate (Na₂S₂O₃) as a stop reagent. However, due to the excess of acid, some participants observed crystal formation in the organic solvent when concentrating the extract to smaller volumes (to reduce the LOQ). Such a phenomenon was not observed with all types of IF.
- ✓ The formation of crystals should not affect the analysis after their removal, but it could cause clogging in the chromatographic system. In order to remove the excess of acid from the organic phase and to protect the chromatographic device, washing with sodium carbonate (Na₂CO₃) is recommended.


The details of the clean-up procedure using chromatographic column filled with activated silica gel and the point in the analytcal procedure performing it (before or after epoxidation) are relevant topics to be further investigated.

From the 13 satisfactory results reported (Figure 5), 7 were obtained when the column clean-up was applied "after epoxidation", as required by the Roundtable decisions, 3 were obtained when the column clean-up was applied "before epoxidation", and the clean-up step was omitted by 3 participants.

Skipping the clean-up step does not comply with the decisions of the Roundtable and doesn't seem to be a reliable approach for IFs containing possible interferences.

More investigations on column clean-up are necessary to propose the most robust procedure for different varieties of IF.

**Figure 6.** Resuts obtained with/without column clean-up performed before/after epoxidation



## 4.4 Limit of quantification

The limit of quantification (LOQ) for MOAH in IF depends obviously also on the amount of sample (representative for the initial IF sample intake) injected into the chromatographic system and reaching the FID detector. Table 1 presents the injected amounts (calculated by the organisers, based on the answers from the questionnaire) ranging from 0.025 to 1.3 g and resulting in LOQ values ranging from 0.06 to 2 mg/kg per fraction and for total MOAH.

The majority of the laboratories (16) reported LOQs of 0.5 mg/kg per fraction and for total MOAH; 4 laboratories reported no LOQ for total MOAH; 6 laboratories expressed their LOQ for total MOAH as the sum of the LOQs per fractions.

Most of the participants reported the same LOQ for each individual fraction. In general, most of them evaluate different LOQs for different type of IF, depending on the matrix interferences. Some laboratories evaluate the LOQ based on a visual approach (Figure 7, option 2), which indicates the hump when compared to the signal of the blank and takes into account any detected interferences that could not be removed by the procedure. These laboratories report usually different LOQs (i) for different IF samples, depending on the interferences in the sample and/or (ii) for different replicates of the same sample, depending on the blank.




Figure 7 Number of laboratories using a specific approach to evaluate LOQs per MOAH fraction


**Table 1.**Sample equivalent injected (SEI, in g) in the chromatographic system as<br/>calculated by the ILC organizer compared to the reported LOQs per fraction<br/>and for total MOAH (expressed in in mg kg<sup>-1</sup>).

SEI	LOQ C10-C16	LOQ C16-C25	LOQ C25-C35	LOQ C35-C50	LOQ total MOAH
0.24	1	1	1	1	1
0.33	0.5	0.5	0.5	0.5	0.5
0.59	No LOQ	1	1	1	1
0.25	0.5	0.5	0.5	0.5	No LOQ
0.5	0.5	0.5	0.5	0.5	0.5
0.38	0.5	0.5	0.5	0.5	0.5
Not enough data to calculate	0.5	0.5	0.5	0.5	0.5
0.7	0.07	0.07	0.07	0.07	0.07
Not enough data to calculate	0.5	0.5	0.5	0.5	0.5
0.2	0.5	0.5	0.5	0.5	0.5
0.375	0.2	0.2	0.2	0.2	0.8
0.25	0.15	0.15	0.15	0.15	0.15
1.32	0.5	0.5	0.5	0.5	1
0.16	0.5	0.5	0.5	0.5	1
0.27	1	0.5	0.5	0.5	0.5
0.36	0.5	0.5	0.5	0.5	0.5
0.1	No LOQ				
0.5	No LOQ				
0.025	0.5	0.5	0.5	0.5	No LOQ
0.025	0.04	0.08	0.06	0.07	0.26
0.054	2	2	2	2	2
0.83	0.5	0.5	0.5	0.5	0.5
0.267	0.1	0.1	0.1	0.1	0.5
Not enough data to calculate	0.05	0.05	0.05	0.05	0.2
0.25	0.15	0.15	0.15	0.15	1
0.2	0.2	0.4	0.2	0.4	1.2

## 4.5 Laboratory experience

Figure 8 indicates that most of the participants have at least five years of experience in the determination of MOSH/MOAH in different type of matrices, such as rice, cereals, oil and fats or paperboards. However, some of them were not used to determine MOAH in infant formula.

It is worth noting that satisfactory results were reported by accredited laboratories as well as participants having only recently implemented their method of analysis, and/or having analysed only a few IF samples in 2019. Only one laboratory reported significantly underestimated values for the five measurands investigated, while claiming to have performed 800 analyses of IF samples over the past 12 months.



## 5 Conclusions

This successful exploratory interlaboratory comparison was organised for the determination of MOAH in commercial IF. The satisfactory results reported and the experimental details provided in the on-line questionnaire were thoroughly scrutinised to identify the relevant experimental steps to be applied as listed below. An analytical protocol will be drafted and then reviewed also by expert laboratories. Afterwards, this harmonised protocol will be validated in a ring-trial. The resulting standard operating procedure will enable the comparability of MOAH in IF results obtained by different laboratories.

A number of experimental conditions (listed hereafter) remain to be discussed and further agreed on:

	Experimental conditions of the steps in the procedure to be followed	Parameter to be agreed
1	hot water reconstitution of the IF – 5 g powder IF in 10 mL hot water at XX $^\circ\!\mathrm{C}$	temperature ? (40 - 60 °C)
2	Alkaline digestion and saponification of the reconstituted IF with KOH (XX g) in saturated ethanolic solution or 50 %	KOH quantity? (1.5 - 3 g)
	aqueous solution in the presence of ethanol at 60 °C for XX min; preparation of saturated EtOH solution (X g KOH / mL EtOH)	saponification time? (30 - 60 min)
3	extraction of the saponified solution with XX mL hexane	V (hexane) ?
4	epoxidation of the organic phase in ethanol with m-CPBA	40 °C ?
	(previously purified/washed in hexane, if needed) at XX °C for XX min ;	15 min ?
	quantity of m-CPBA ( XX g) to be determined depends on whether the column clean-up is before or after the epoxidation	g m-CPBA
5.	Addition of stop reagents - sodium thiosulfate and sodium carbonate - after epoxidation	amount
	washing of the organic phase with ethanol/water after epoxidation required?	Y/N?
6.	Column cleanup and sample enrichment	Before/after epoxidation or both
	column clean-up on XX g of activated silica and elution with DCM/hexane	m(Silica) = 3 or 12 g?
7	0.5 g sample equivalent reaching FID	
8.	Quantification of the MOAH against methyl naphtalenes or TBB	Equivalence to be demonstrated
	Quantification of the total MOAH based on the integration of the entire hump	
9.	Mineral oil solution in hexane with known MOAH content to be proposed as a reference for LOQ determination	Composition /concentration

## Acknowledgements


The EURL-FCM acknowledges the contribution of JRC's Reference Material Unit for processing the powder infant formula and delivering promptly high quality proficiency test items, just before the March 2020 lockdown. Furthermore, the 27 laboratories listed hereafter are kindly acknowledged for their participation to this exercise.

Organisation	Country
Graz University of Technology	Austria
Primoris	Belgium
Sciensano	Belgium
ITERG	France
NQAC NESTLE France Laboratory	France
Bavarian Health and Food Safety Authority	Germany
bilacon GmbH	Germany
Bundesinstitut für Risikobewertung (BfR)	Germany
Chemisches und Veterinäruntersuchungsamt Münsterland- Emscher-Lippe (CVUA-MEL)	Germany
CVUA Stuttgart	Germany
Eurofins WEJ Contaminants GmbH	Germany
Fraunhofer IVV	Germany
GALAB Laboratories GmbH	Germany
GBA Gesellschaft für Bioanalytik mbH	Germany
Institut Kirchhoff Berlin GmbH	Germany
Landesbetrieb Hessisches Landeslabor	Germany
mas GmbH	Germany
SGS Institut Fresenius GmbH	Germany
Dublin Public Analyst's Laboratrory	Ireland
NEOTRON SPA	Italy
Unversity of Udine	Italy
NOFALAB	Netherland
Eurofins Lab Zeeuws-Vlaanderen (CNL027)	Netherlands
Wageningen Food Safety Research	Netherlands
Nestlé Research	Switzerland
Official Food Control Authority of the Canton of Zurich	Switzerland
Swiss Quality Testing Services	Switzerland

#### Annex 1: Invitation letter



#### Annex 2: Instructions to participants



The reporting website <u>https://europa.eu/!QG86xB</u> will be open on March 30, 2020.

To access the webpage you need the following personal password key: «Part\_key».

The system will guide you through the reporting procedure. Then complete the corresponding questionnaire. Do not forget to submit and confirm when required.

Only results accompanied by the filled-in questionnaire will be taken into account for further evaluation!

At present, the deadline for submission of results is set to May 10, 2020.

A report to participants will be circulated shortly after the end of the round to present

(i) the reported values from all participants with their lab codes and

(ii) a proposed SOP to be further validated.

However, the laboratory code will be disclose only to the respective participant, to preserve the confidentiality of the data reported.

Your participation in this project is greatly appreciated.

Do not hesitate to contact me for further information.

With kind regards,

/signed electronically in Ares/

Dr. Stefanka Bratinova JRC IF 2020/01 Coordinator

Cc:

H. Emons (Head of Unit, Food & Feed Compliance, F.5),

E. Hoekstra (Operating Manager EURL-FCM)

P. Robouch (Standardisation group team leader)

European Commission, JRC-Geel, Belgium. Telephone: (32) 14571800. e-mail: jrc-eurl-fcm@ec.europa.eu. URL: https://ec.europa.eu/irc/en/eurl/food-contact-materials

## Annex 3: Confirmation of receipt form

JC Dir	UROPEAN COMMISSI DINT RESEARCH CENTRE rectorate F – Health, Consumers a uropean Union Reference Labora	nd Reference Materials	EURIC EURICE LE European Union Reference Le for Food Contact Ma
Attn.: «Title» «Firstname» «Organisation» «Country»	«Surname»		
Subject: Part	icipation in JRC IF 202	0/01 – "Determination of	MOAH in IF"
Please return this form wit laboratory. If samples are d			
Date of package arrival:	//	/2020	
Was the sample damaged?	□ YES	$\Box$ NO	
Remarks			
Signature			
Thank you for returning thi <u>Stefanka-Petkova.BRATIN</u> CC: <u>jrc-eurl-fcm@ec.europ</u>	NOVA@ec.europa.eu		
European Commission, JRC-Geel, B e-mail: jrc-eurl-fcm@ec.europa.eu. L			

#### **Annex 4.** Eusurvey – online questionnaire

to collect experimental details used by the participants to analyse MOAH in IF (https://ec.europa.eu/eusurvey/runner/JRC\_IF\_2020\_01A )

Moaling         Infant Formula         This questionnaire aims to collect the analytical procedure that you used for the determination of MO Infant Formula (IF), in the frame of the present interlaboratory comparison.         Consequently, the JRC intends to identify best practices, that would result in a reliable, robust and harmonised method to be further ring-trial validated.         Thank you for your contribution
This questionnaire aims to collect the analytical procedure that you used for the determination of MO Infant Formula (IF), in the frame of the present interlaboratory comparison. Consequently, the JRC intends to identify best practices, that would result in a reliable, robust and harmonised method to be further ring-trial validated.
Infant Formula (IF), in the frame of the present interlaboratory comparison. Consequently, the JRC intends to identify best practices, that would result in a reliable, robust and harmonised method to be further ring-trial validated.
Consequently, the JRC intends to identify best practices, that would result in a reliable, robust and harmonised method to be further ring-trial validated.
harmonised method to be further ring-trial validated.
Thank you for your contribution
Stefanka.BRATINOVA@ec.europa.eu
ILC-coordinator of the "MOAH in IF"
A Previous experience
* A.1 Specify your confidential "Participation Key"
* A.2 Institution
* A.3 Your e-mail address
★ A.4 Years of experience with MOSH/MOAH analysis
<ul> <li>no experience</li> </ul>
less than 1 year
1 - 2 years
<ul> <li>1 - 2 years</li> <li>3 - 5 years</li> </ul>
1 - 2 years
<ul> <li>1 - 2 years</li> <li>3 - 5 years</li> <li>more than 5 years</li> </ul>
<ul> <li>1 - 2 years</li> <li>3 - 5 years</li> <li>more than 5 years</li> <li>* A.5 Number of samples analysed for MOSH/MOAH in 2019</li> </ul>
<ul> <li>1 - 2 years</li> <li>3 - 5 years</li> <li>more than 5 years</li> <li>* A.5 Number of samples analysed for MOSH/MOAH in 2019</li> <li>less than 10</li> </ul>
<ul> <li>1 - 2 years</li> <li>3 - 5 years</li> <li>more than 5 years</li> <li>A.5 Number of samples analysed for MOSH/MOAH in 2019</li> <li>less than 10</li> <li>10 to 50</li> </ul>
<ul> <li>1 - 2 years</li> <li>3 - 5 years</li> <li>more than 5 years</li> <li>A.5 Number of samples analysed for MOSH/MOAH in 2019</li> <li>less than 10</li> </ul>

#### A.6 Your experience depending on the type of matrices

lassification according to the EURL-FCM Guidance document	
- no experience	
- very little experience	
- moderate experience	
- high expertise	
	Rank (0-3) the matrices you are most experienced in
*Dry, low fat content sample (< 4% oils/fat)	
*Higher fat/oil content sample (> 4 % oils/fat)	
*Oils & Fats	
*Paperboard	
*Infant Formula	

* A.8 S	tatus of your method for MOAH in IF
	method under development
	method validated
C	method accredited
C	other (e.g. direct implementation of an SOP, developed by other lab)
* A.9 F	lease specify
BS	ample preparation
* B.1 S	ample intake
	9
* B.2 S	ource of the Internal & Verification Standards
C	commercial
C	home made from individual compounds
* B 3 F	lease give reference to the commercial standard. Is it diluted before use?
* B.3 F	lease give reference to the commercial standard. Is it diluted before use?
* B.3 F	lease give reference to the commercial standard. Is it diluted before use?
* B.3 F	lease give reference to the commercial standard. Is it diluted before use?
	Please give reference to the commercial standard. Is it diluted before use?
* B.4 F	
* B.4 F	lease describe the Internal & Verification Standards (compounds and concentration levels of the
* B.4 F	lease describe the Internal & Verification Standards (compounds and concentration levels of the
* B.4 F	lease describe the Internal & Verification Standards (compounds and concentration levels of the
* B.4 F	lease describe the Internal & Verification Standards (compounds and concentration levels of the
* B.4 F	lease describe the Internal & Verification Standards (compounds and concentration levels of the
* B.4 F soluti	Please describe the Internal & Verification Standards (compounds and concentration levels of the on used for spiking)
* B.4 F soluti	lease describe the Internal & Verification Standards (compounds and concentration levels of the
* B.4 F soluti	Please describe the Internal & Verification Standards (compounds and concentration levels of the on used for spiking)
* B.4 F soluti	Please describe the Internal & Verification Standards (compounds and concentration levels of the on used for spiking)
* B.4 F soluti	Please describe the Internal & Verification Standards (compounds and concentration levels of the on used for spiking)
* B.4 F soluti	Please describe the Internal & Verification Standards (compounds and concentration levels of the on used for spiking)
* B.4 F soluti	Please describe the Internal & Verification Standards (compounds and concentration levels of the on used for spiking)

0	perimental path chosen Reconstitution, Extraction & Saponification simultaneous
	(IF + IS + ethanol/water + KOH + organic solvent)
	Reconstitution and saponification
	(IF + IS + ethanol/water + KOH), followed by extraction (organic solvent)
$\odot$	Reconstitution (IF + IS + ethanol/water), followed by extraction in organic solvent. Saponificatio
	n only on the organic extract (organic phase + KOH + water)
	Saponification (IF + IS + KOH) followed by extraction ( organic solvent) without reconstitution
0	Simultaneous saponification and extraction (IF + IS + KOH + organic solvent) without reconstitution
0	Other (except for additional saponification and washing as the questions will follow)
* C.2 Int	termediate steps
$\odot$	none
$\bigcirc$	shaking/heating before adding KOH without organic solvent (for reconstitution of the Infant
	Formula)
$\odot$	shaking/heating before adding KOH with organic phase (for partial fat extraction)
0	other
* C 3 Te	emperature
	oC
* C.4 Ti	me
	min
* C.5 If '	other" specify other intermediate steps
	ease describe in detail any other sample treatment path applied by you
* C.6 Pl	ease describe in detail any other sample treatment bath abblied by you
* C.6 Pl	ease describe in detail any other sample treatment path applied by you

C.7 Table of the reagent for the saponification&extraction step

	Solvent	Concentraction, %	Volume, mL
*water			
★ethanol			
★KOH in			
★organic solvent			

* C.8 Amount of KOH	
Fixed amount for all m	
Adjusted to the fat cor	ntent in the sample
*C.9 Temperature during sape	onification
	oC
* C.10 Time for saponification	
	min
<ul> <li>C.11 Aqueous/Organic phase</li> <li>gentle shaking</li> </ul>	e mixing during saponification/extraction, ensured by:
<ul> <li>vigorous shaking</li> </ul>	
<ul> <li>vigorous shaking</li> <li>ultrasonic</li> </ul>	
<ul> <li>reflux</li> </ul>	
other	
<ul> <li>C.13 Phase separation, using</li> <li>separatory funnels</li> <li>only vials &amp; pipettes</li> <li>C.14 Please specify the type</li> </ul>	g e of pipettes you are using during the procedure
★ C.15 Further steps	
★ C.15 Further steps (multiple choice)	
(multiple choice)	step on organic phase
(multiple choice) <ul> <li>none</li> <li>second saponification</li> <li>washing of the organic</li> </ul>	c extract with solvent
(multiple choice) <ul> <li>none</li> <li>second saponification</li> <li>washing of the organic</li> </ul>	
(multiple choice) <ul> <li>none</li> <li>second saponification</li> <li>washing of the organic</li> <li>re-concentration of the</li> </ul>	c extract with solvent e organic extract before next step
<ul> <li>none</li> <li>second saponification</li> <li>washing of the organic</li> </ul>	c extract with solvent e organic extract before next step

* C.18 How many tim	es	
* C.19 Till what volum		
	mL	
* C.20 How is the pre	-concentration done?	
flow of nitroge	en	
<ul> <li>rotavapor</li> <li>other</li> </ul>		
* C.21 Please specify	"other"	
C.22 Please describ	e any deviations from the above mentioned steps	
D Epoxidatio	n	
* D.1 Which part of th	e extract undergoes epoxidation?	
all the organi	c phase	
all the organi		
<ul><li>all the organi</li><li>an aliquot of</li></ul>	c phase the organic phase	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify to</li> </ul>	c phase	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify to</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify to</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify a either in fraction number</li> <li>* D.3 Epoxidation age</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent?	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify to</li> <li>either in fraction number</li> <li>D.3 Epoxidation age</li> <li>in dichloromer</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent?	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify a either in fraction number</li> <li>* D.3 Epoxidation age</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent?	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify to</li> <li>either in fraction number</li> <li>D.3 Epoxidation age</li> <li>in dichloromer</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify weither in fraction number</li> <li>b.3 Epoxidation age</li> <li>in dichlorome</li> <li>in ethanol</li> <li>* D.4 Do you purify monopolic</li> <li>No</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane	
<ul> <li>all the organi</li> <li>an aliquot of</li> </ul> D.2 Please specify a either in fraction number * D.3 Epoxidation age <ul> <li>in dichlorome</li> <li>in ethanol</li> </ul> * D.4 Do you purify m	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane	
<ul> <li>all the organi</li> <li>an aliquot of</li> </ul> D.2 Please specify velther in fraction number • D.3 Epoxidation age <ul> <li>in dichlorome</li> <li>in ethanol</li> </ul> * D.4 Do you purify m <ul> <li>No</li> <li>Yes</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane CPBA before use?	
<ul> <li>all the organi</li> <li>an aliquot of</li> <li>D.2 Please specify velther in fraction number</li> <li>b.3 Epoxidation age</li> <li>in dichlorome</li> <li>in ethanol</li> <li>* D.4 Do you purify monopolic</li> <li>No</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane CPBA before use?	
<ul> <li>all the organi</li> <li>an aliquot of</li> </ul> D.2 Please specify velther in fraction number * D.3 Epoxidation age <ul> <li>in dichlorome</li> <li>in ethanol</li> </ul> * D.4 Do you purify m <ul> <li>No</li> <li>Yes</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane CPBA before use?	
<ul> <li>all the organi</li> <li>an aliquot of</li> </ul> D.2 Please specify velther in fraction number * D.3 Epoxidation age <ul> <li>in dichlorome</li> <li>in ethanol</li> </ul> * D.4 Do you purify m <ul> <li>No</li> <li>Yes</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane CPBA before use?	
<ul> <li>all the organi</li> <li>an aliquot of</li> </ul> D.2 Please specify velther in fraction number * D.3 Epoxidation age <ul> <li>in dichlorome</li> <li>in ethanol</li> </ul> * D.4 Do you purify m <ul> <li>No</li> <li>Yes</li> </ul>	c phase the organic phase what part from the total organic phase is taken for epoxidation r or how many mL from the total extract in mL ent (mCPBA) in which solvent? thane CPBA before use?	

	solvent	concentration (g/L)	volume added (mL)
*organic extract			
*mCPBA			
*Na2S2O3 *Na2CO3			
*other			
- Otilei			
	Ω.		
* D.8 please specify "othe	ər"		
* D.9 at what temperature	e the epoxidation is carried	out?	
	oC		
* D.10 for how long?			
-D.TO IOT HOW IONG?	min		
* D.11 Do you wash the o	organic phase after the epox	xidation?	
O Yes	5		
No			
0 110			
D 10 Diseas describe th			
* D.12 Please describe th	ie wasning step		
D 12 Da vau ara canac	ntrata tha araania ahaaa aft	er energiation?	
	ntrate the organic phase aft	er epoxidation?	
O No			
Yes			
D.14 till what volume (u	L)		
* D.15 How is the pre-cor	ncentration done?		
blow of nitrogen			
rotavapor			
other			
* D.16 Please specify "ot	her"		
E Column clean	-up		
	i-up		
E Column clean	n-up		

<ul> <li>* E.2 Which part of the organic phase undergoes clean-up?</li> <li>all the organic phase</li> <li>an aliquot of the organic phase</li> </ul>							
	nat part from the total organic p or how many mL from the total extract in						
★ E.4 Type and amount	of the sorbents loaded onto the	e column					
<ul> <li>★ E.5 activated sorbent</li> <li>O No</li> <li>O Yes</li> </ul>	?						
* E.6 activated for how	min						
* E.7 activated at what	oC						
E.8 Sequence of the solvent for washin							
In the column "volume collected", please specify 1 2 3 4	only the volume collected for further processing Eluent	; some cells SHOULD be empty Volume used (mL)	Volume collected (mL)				

* E.9 Do you pre-concer	ntrate the eluate before furth	er processing?	
O No			
Yes			
* E.10 till what volume ?			
	mL		
* E.11 How is the pre-co	pagettation dans?		
E.T How is the pre-cc flow of nitrogen	incentration done?		
<ul> <li>now of hitrogen</li> <li>rotavapor</li> </ul>			
© other			
* E.12 Please specify "o	ther"		
F Analytical se	tup for MOSH/MO	AH separation	
<ul> <li>F.1 Separation perform</li> </ul>	ned		
before epoxidat			
after epoxidation	n		
500			
★ F.2 Set-up used on-line			
	lection of fractions in auto-s	ampler & injection into GC fron	a vial)
<ul> <li>seril-online (col</li> <li>off-line</li> </ul>	lection of fractions in acto-s	ampler a injection into do iron	i viai)
* F.3 Please describe th	e instrument you used for th	ne analyses	
G Manual MOS	H/MOAH separation	on	
*G.1 Column used			
*G.2 Type of and quant	ities of the sorbents filled in	the column	
C 2 Sequence of chuerte			
G.3 Sequence of eluents			
In the column "volume collected", please specify	only the volume collected for MOSH and MO	DAH analyses; some cells SHOULD be	
empty	Eluent	Volume used (mL)	Volume collected (mL)
1			
2 3			
4			
	1	1	

	ion of MOAH fraction, please describe
* G.5 How you control the sta	art and the end of the MOAH fraction
*G.6 Do you pre-concentrate	e the MOAH fraction?
O No	
Yes	
*G.7 till what volume ?	
	mL
*G.8 How is the pre-concent	tration done?
blow of nitrogen	
<ul><li>rotavapor</li><li>other</li></ul>	
* G.9 Please specify "other"	
H Details of HPLC	for the on-line MOSH/MOAH separation
	mn used and its dimentions
*H.1 Type of the HPLC colur	
* H.1 Type of the HPLC colur	
* H.1 Type of the HPLC colur	
	ted
<ul> <li>* H.1 Type of the HPLC colur</li> <li>* H.2 Volume of extract inject</li> </ul>	ted ul
*H.2 Volume of extract inject	
*H.2 Volume of extract inject	

*H.5 When the MOAH fraction collection begins?         Just after MOSH         Using the Retention Time of TBB         Using the Retention Time of DEHB         Other         *H.6 Please describe "other"         Image: Details of GC         *I.1 Injection system used         direct coupling with HPLC         odd on-column         PTV with liner         split         other         *I.2 if "other", specify		
<ul> <li>Just after MOSH</li> <li>Using the Retention Time of TBB</li> <li>Using the Retention Time of DEHB</li> <li>Other</li> </ul> *H.6 Please describe "other" IDetails of GC *I.1 Injection system used <ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> *I.2 if "other", specify <ul> <li>if "other", specify</li> <li>if "other", specify</li> <li>if "other", specify</li> <li>i.13 Volume injected in GC (in uL)</li> <li>uL</li> </ul> I.4 Is the total MOAH fraction transfered to the GG via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> *I.5 What part of the total MOAH fraction is injected in the GC port? Plaese indicate 1/2: 1/3: 1/4: 1/6 etc <ul> <li>fraction</li> </ul> *I.6 Type of column and dimentions <ul> <li>[</li></ul>		
<ul> <li>Just after MOSH</li> <li>Using the Retention Time of TBB</li> <li>Using the Retention Time of DEHB</li> <li>Other</li> </ul> *H.6 Please describe "other" IDetails of GC *I.1 Injection system used <ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> *I.2 if "other", specify <ul> <li>if "other", specify</li> <li>if "other", specify</li> <li>if "other", specify</li> <li>i.13 Volume injected in GC (in uL)</li> <li>uL</li> </ul> I.4 Is the total MOAH fraction transfered to the GG via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> *I.5 What part of the total MOAH fraction is injected in the GC port? Plaese indicate 1/2: 1/3: 1/4: 1/6 etc <ul> <li>fraction</li> </ul> *I.6 Type of column and dimentions <ul> <li>[</li></ul>		
<ul> <li>Just after MOSH</li> <li>Using the Retention Time of TBB</li> <li>Using the Retention Time of DEHB</li> <li>Other</li> </ul> *H.6 Please describe "other" IDetails of GC *I.1 Injection system used <ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> *I.2 if "other", specify <ul> <li>if "other", specify</li> <li>if "other", specify</li> <li>if "other", specify</li> <li>i.13 Volume injected in GC (in uL)</li> <li>uL</li> </ul> I.4 Is the total MOAH fraction transfered to the GG via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> *I.5 What part of the total MOAH fraction is injected in the GC port? Plaese indicate 1/2: 1/3: 1/4: 1/6 etc <ul> <li>fraction</li> </ul> *I.6 Type of column and dimentions <ul> <li>[</li></ul>	*H.5 Wh	en the MOAH fraction collection begins?
Using the Retention Time of DEHB Cther  H.6 Please describe "other"  IDetails of GC  IDetails		
Other • H.6 Please describe "other"   IDetails of GC   • 1.1 Injection system used   Injection sys	0ι	Jsing the Retention Time of TBB
I Details of GC  I.1 Injection system used Girect coupling with HPLC Girect doubling do	0 (	Other
<ul> <li>I.1 Injection system used <ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> </li> <li>1.2 if "other", specify <ul> <li>1.3 Volume injected in GC (in uL)</li> <li>uL</li> </ul> </li> <li>1.4 Is the total MOAH fraction transfered to the GC via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> </li> <li>1.5 What part of the total MOAH fraction is injected in the GC port? Please indicate 1/2; 1/3; 1/4; 1/5 etc fraction </li> <li>*1.6 Type of column and dimentions </li> </ul>	*H.6 Plea	ase describe "other"
<ul> <li>I.1 Injection system used <ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> </li> <li>1.2 if "other", specify <ul> <li>1.3 Volume injected in GC (in uL)</li> <li>uL</li> </ul> </li> <li>1.4 Is the total MOAH fraction transfered to the GC via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> </li> <li>1.5 What part of the total MOAH fraction is injected in the GC port? Please indicate 1/2; 1/3; 1/4; 1/5 etc fraction </li> <li>*1.6 Type of column and dimentions </li> </ul>		
<ul> <li>I.1 Injection system used <ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> </li> <li>1.2 if "other", specify <ul> <li>1.3 Volume injected in GC (in uL)</li> <li>uL</li> </ul> </li> <li>1.4 Is the total MOAH fraction transfered to the GC via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> </li> <li>1.5 What part of the total MOAH fraction is injected in the GC port? Please indicate 1/2; 1/3; 1/4; 1/5 etc fraction </li> <li>*1.6 Type of column and dimentions </li> </ul>		
<ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> •1.2 if "other", specify •1.3 Volume injected in GC (in uL) <ul> <li>uL</li> </ul> 1.4 Is the total MOAH fraction transfered to the GC via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> •1.5 What part of the total MOAH fraction is injected in the GC port? Please indicate 1/2; 1/3; 1/4; 1/5 etc <ul> <li>fraction</li> </ul> •1.6 Type of column and dimentions	Deta	ails of GC
<ul> <li>direct coupling with HPLC</li> <li>cold on-column</li> <li>PTV with liner</li> <li>split</li> <li>other</li> </ul> •1.2 if "other", specify •1.3 Volume injected in GC (in uL) <ul> <li>uL</li> </ul> 1.4 Is the total MOAH fraction transfered to the GC via on-line interface <ul> <li>YES</li> <li>NO</li> </ul> •1.5 What part of the total MOAH fraction is injected in the GC port? Please indicate 1/2; 1/3; 1/4; 1/5 etc <ul> <li>fraction</li> </ul> •1.6 Type of column and dimentions	+ 1 1 Inico	tion system used
cold on-column PTV with liner split other •1.2 if "other", specify .1.3 Volume injected in GC (in uL) uL 1.4 Is the total MOAH fraction transfered to the GC via on-line interface YES NO •1.5 What part of the total MOAH fraction is injected in the GC port? Please indicate 1/2; 1/3; 1/4; 1/5 etc fraction •1.6 Type of column and dimentions		
<ul> <li>PTV with liner</li> <li>split</li> <li>other</li> <li>1.2 if "other", specify</li> <li>1.3 Volume injected in GC (in uL)</li> <li>uL</li> <li>1.4 Is the total MOAH fraction transfered to the GC via on-line interface</li> <li>YES</li> <li>NO</li> <li>1.5 What part of the total MOAH fraction is injected in the GC port?</li> <li>Please indicate 1/2; 1/3; 1/4; 1/5 etc</li> <li>fraction</li> <li>1.6 Type of column and dimentions</li> </ul>		
<ul> <li>split</li> <li>other</li> <li>1.2 if "other", specify</li> <li>1.3 Volume injected in GC (in uL)</li> <li>uL</li> <li>1.4 Is the total MOAH fraction transfered to the GC via on-line interface</li> <li>YES</li> <li>NO</li> <li>1.5 What part of the total MOAH fraction is injected in the GC port?</li> <li>Please indicate 1/2; 1/3; 1/4; 1/5 etc</li> <li>fraction</li> <li>1.6 Type of column and dimentions</li> </ul>		
<ul> <li>other</li> <li>1.2 if "other", specify</li> <li>.1.3 Volume injected in GC (in uL)</li> <li>uL</li> <li>1.4 Is the total MOAH fraction transfered to the GC via on-line interface</li> <li>YES</li> <li>NO</li> <li>.1.5 What part of the total MOAH fraction is injected in the GC port?</li> <li>Please indicate 1/2; 1/3; 1/4; 1/5 etc</li> <li>fraction</li> <li>*1.6 Type of column and dimentions</li> </ul>		
• 1.3 Volume injected in GC (in uL) uL 1.4 Is the total MOAH fraction transfered to the GC via on-line interface • YES • NO • 1.5 What part of the total MOAH fraction is injected in the GC port? Please indicate 1/2; 1/3; 1/4; 1/5 etc fraction • 1.6 Type of column and dimentions		
I.4 Is the total MOAH fraction transfered to the GC via on-line interface  ○ YES ○ NO    I.5 What part of the total MOAH fraction is injected in the GC port?  Please indicate 1/2; 1/3; 1/4; 1/5 etc  fraction    I.6 Type of column and dimentions	* I.2 if "ot	her", specify
I.4 Is the total MOAH fraction transfered to the GC via on-line interface  ○ YES ○ NO    I.5 What part of the total MOAH fraction is injected in the GC port?  Please indicate 1/2; 1/3; 1/4; 1/5 etc  fraction    I.6 Type of column and dimentions		
I.4 Is the total MOAH fraction transfered to the GC via on-line interface  ○ YES ○ NO    I.5 What part of the total MOAH fraction is injected in the GC port?  Please indicate 1/2; 1/3; 1/4; 1/5 etc  fraction    I.6 Type of column and dimentions	* I.3 Volu	me injected in GC (in uL)
<ul> <li>YES</li> <li>NO</li> <li>*1.5 What part of the total MOAH fraction is injected in the GC port?</li> <li>Please indicate 1/2; 1/3; 1/4; 1/5 etc</li> <li>fraction</li> <li>*1.6 Type of column and dimentions</li> </ul>		
<ul> <li>YES</li> <li>NO</li> <li>*1.5 What part of the total MOAH fraction is injected in the GC port?</li> <li>Please indicate 1/2; 1/3; 1/4; 1/5 etc</li> <li>fraction</li> <li>*1.6 Type of column and dimentions</li> </ul>		
<ul> <li>YES</li> <li>NO</li> <li>*1.5 What part of the total MOAH fraction is injected in the GC port?</li> <li>Please indicate 1/2; 1/3; 1/4; 1/5 etc</li> <li>fraction</li> <li>*1.6 Type of column and dimentions</li> </ul>	1.4 le th	e total MOAH fraction transferred to the GC via on-line interface
<ul> <li>NO</li> <li>* I.5 What part of the total MOAH fraction is injected in the GC port?     Please indicate 1/2; 1/3; 1/4; 1/5 etc     fraction     </li> <li>* I.6 Type of column and dimentions</li> </ul>		
I.5 What part of the total MOAH fraction is injected in the GC port?      Please indicate 1/2; 1/3; 1/4; 1/5 etc     fraction      I.6 Type of column and dimentions		
Please indicate 1/2; 1/3; 1/4; 1/5 etc fraction * I.6 Type of column and dimentions		
I.6 Type of column and dimentions	* I.5 Wha	t part of the total MOAH fraction is injected in the GC port?
*I.6 Type of column and dimentions	Please i	
		fraction
*I.7 Type of pre-column	∗ I.6 Туре	of column and dimentions
* I.7 Type of pre-column		
* I.7 Type of pre-column		
	* І.7 Турє	e of pre-column

* 1.8	Oven	temperature	program
-------	------	-------------	---------

\* I.9 Additional information

(multiple choice)

have a retention gap installed

vent the injected solvent before entering the separation column

\* I.10 Do you have problem with

(multiple choice)

the baseline

the the peak tailing/broadening

the solvent peak

the blank

interferences

\* I.11 Please describe in more detail the problem

#### **J** Quantification

\* J.1 How do you quantify MOAH? Against which standard?

\* J.2 Did you remove any riding peaks ?

\*J.3 How do you calculate the total MOAH

as the sum of different fractions applying the lower bond approach (if less than LOQ then set to zero)

based on the integration of the entire chromatogram (from C10 to C50)

\*J.4 Peak/Hump integration

Manual

Automatic

\* J.5 Software used for peak evaluation

\* J.6 Baseline/blank compensation

- Manual blank correction
- Automatic software compensation

\* J.7 If "manual", please explain "how"

- \*J.8 If "automatic", do you visually check the correctness of the peak/hump integration for EACH sample?
  - Yes

No

## K Limit of Quantification (LOQ) and measurement uncertainty (U)

K.1 Please report LOQ for different fractions and the total

	LOQ
1. MOAH $\ge$ n-C10 to $\le$ n-C16	
2. MOAH > n-C16 to $\leq$ n-C25	
3. MOAH > n-C25 to $\leq$ n-C35	
4. MOAH > n-C35 to $\leq$ n-C50	
5. Total MOAH	

\* K.2 How do you evaluate the LOQ for the individual fraction of MOAH in IF? Which of the following statement is correct?

Multiple answers are accepted

- 1. you spike a blank IF with mineral oil at levels close to LOQ of total MOAH to estimate the LOQ per fraction
- 2. you evaluate the LOQ as the concentration related to the signal of the hump, that could be visually distinguished from the signal of the blank.
- 3. LOQ is the same for each MOAH fraction
- 4. LOQ is the same for each IF sample
- 5. LOQ is the same for each IF sample in general, however when interferences are identified, the LOQ of the respective fractions were adjusted depending on the interferences.
- 6. LOQ is evaluated for each sample individually, depending on the interferences.
- \* K.3 What is the spiking level of the mineral oil and the type of the mineral oil? What was the MOAH content in it?

*K.5 Do you e	strapolate the estimated LOQ to the other fractions?
Yes	
No	
* K.6 LOQ for to	otal MOAH is set as:
max(L0)	OQ) of the various fractions
sum(L0)	DQ) of the various fractions
based	on the integration of the entire hump
other	
*K.7 Please de	escribe "other"
*K.8 Estimated	d relative intermediate precision around the LOQ
	%
🔲 validati	te analyses (repeatability) ion study (intermediate precision) revious proficiency tests
expert	
	ing to Guide for the expression of the Measurement Uncertainty (GUM)
other	
*K.10 Which C	Quality Control measures do you apply in general during analyses of IF for MOAH?
	for the intensity of peaks - IS and verification standards
recove	ry
reagen	t blank
	te analyses
QC sat	
	r the determination of MOSH/MOAH in other matrices
<ul><li>PTs for</li><li>other</li></ul>	you evaluate recovery for the MOAH in IF?
<ul><li>PTs for</li><li>other</li></ul>	you evaluate recovery for the MOAH in IF?

Г

\*K.12 Do you always analyse replicate sample when the result for MOAH in IF is positive?

\*K.13 Specify which QC sample was used with the current analyses

\*K.14 Please mention the successful participation in a PT for MOSH/MOAH in other food matreces

\*K.15 If "other", specify

L Other

L.1 Any other comment from your side

Thank you for your contribution. Rest assured that this information will be treated with due confidentiality



LabCode	Result	MU (k=2)	Rep1	Rep2	Rep3	Method
1	2.7	1.1	2.7	2.6	2.7	ON-line LC-GC-FID
2	3	1.4	2.2	3.7	3.1	ON-line LC-GC-FID
3	3.09	0.49	3.17	3.08	3.02	ON-line LC-GC-FID
4	4.1	0.7	4.1	4	4	ON-line LC-GC-FID
5	4.47		4.54	4.476	4.395	ON-line LC-GC-FID
6	2.7	0.8	2.7	2.8	2.4	ON-line LC-GC-FID
7	2.78	0.14	2.82	2.74	2.77	ON-line LC-GC-FID
8	3.67	1.1	3.69	3.64		
9	1.96	0.78	1.94	1.97	1.97	ON-line LC-GC-FID
10	1.42	25	1.6	1.24	1.42	ON-line LC-GC-FID
11	4.919	0				OFF-line GC-FID
12	3.888	1.283	4.313	3.645	3.706	ON-line LC-GC-FID
13	2.62	0.33	2.3	2.95	2.61	ON-line LC-GC-FID
14	0.64		0.59	0.73	0.59	ON-line LC-GC-FID
15	< 1.2		< 1.2	< 1.2	< 1.2	OFF-line GC-FID
16	2.26	0.84	2.08	2.54	2.06	ON-line LC-GC-FID
17	2.47	0.3	2.44	2.39	2.57	ON-line LC-GC-FID
18	3.5	1.4	3.4	3.5	3.6	ON-line LC-GC-FID
19	3.2	1.6	3.1	3.2	3.4	ON-line LC-GC-FID
20	1.7	0.2	1.6	1.8		
21	2.7	1.13	2.9	2.8	2.5	ON-line LC-GC-FID
22	3.1		3.1	3.1	3.1	ON-line LC-GC-FID
23	< 0.5		< 0.5	< 0.5	< 0.5	Semi-ON line LC-GC-FID
24	3.1	0.9	3.1	3.3	3	ON-line LC-GC-FID
25	1.73	0.43	1.72	1.76	1.71	ON-line LC-GC-FID
26	3.3	0.66	3.28	3.43	3.22	ON-line LC-GC-FID
27	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID

Annex 5. Results as reported by the participants for total MOAH in IF (in mg kg<sup>-1</sup>)

LabCode	Result	MU (k=2)	Rep1	Rep2	Rep3	Method
1	2	0.8	2.1	2	2.1	ON-line LC-GC-FID
2	2.5	1.4	1.8	3.1	2.5	ON-line LC-GC-FID
3	2.14	0.34	2.19	2.14	2.11	ON-line LC-GC-FID
4	3.2	0.5	3.2	3.1	3.2	ON-line LC-GC-FID
5	3.438		3.5	3.39	3.424	ON-line LC-GC-FID
6	2.1	0.6	2.1	2.2	1.9	ON-line LC-GC-FID
7	2.15	0.1	2.17	2.12	2.17	ON-line LC-GC-FID
8	3.12		3.17	3.07		
9	1.61	0.64	1.61	1.61	1.61	ON-line LC-GC-FID
10	0.88	25	0.98	0.78	0.88	ON-line LC-GC-FID
11	1.759	0				OFF-line GC-FID
12	3.023	0.997	3.369	2.784	2.915	ON-line LC-GC-FID
13	1.85	0.33	1.49	2.13	1.94	ON-line LC-GC-FID
14	0.5		0.37	0.59	0.43	ON-line LC-GC-FID
15	< 0.4		< 0.4	< 0.4	< 0.4	OFF-line GC-FID
16	1.39	0.54	1.23	1.52	1.2	ON-line LC-GC-FID
17	1.93	0.3	1.92	1.82	2.05	ON-line LC-GC-FID
18	2.6	1	2.6	2.6	2.7	ON-line LC-GC-FID
19	2.6	1.3	2.5	2.7	2.7	ON-line LC-GC-FID
20	1.4	0.3	1.6	1.3		
21	1.9	0.8	2	2	1.8	ON-line LC-GC-FID
22	2.4		2.4	2.4	2.4	ON-line LC-GC-FID
23	< 0.5		< 0.5	< 0.5	< 0.5	Semi-ON line LC-GC-FID
24	2.4	0.7	2.4	2.6	2.3	ON-line LC-GC-FID
25	1.39		1.37	1.42	1.38	ON-line LC-GC-FID
26	2.5	0.5	2.46	2.57	2.42	ON-line LC-GC-FID
27	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID

Annex 6. Results as reported by the participants for the MOAH C35-C50 fraction in IF (in mg kg<sup>-1</sup>)

LabCode	Result	MU (k=2)	Rep1	Rep2	Rep3	Method
1	0.63	0.25	0.65	0.61	0.63	ON-line LC-GC-FID
2	0.6	0.2	0.4	0.6	0.7	ON-line LC-GC-FID
3	0.95	0.15	0.98	0.94	0.92	ON-line LC-GC-FID
4	0.9	0.2	0.8	0.9	0.8	ON-line LC-GC-FID
5	1.032		1.04	1.086	0.971	ON-line LC-GC-FID
6	0.6	0.2	0.6	0.6	0.5	ON-line LC-GC-FID
7	0.58	0.14	0.63	0.57	0.55	ON-line LC-GC-FID
8	0.54		0.52	0.56		
9	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
10	0.54	25	0.62	0.46	0.54	ON-line LC-GC-FID
11	2.013	0				OFF-line GC-FID
12	0.852	0.281	0.934	0.835	0.788	ON-line LC-GC-FID
13	0.77	0.09	0.82	0.82	0.67	ON-line LC-GC-FID
14	< 0.15		0.19	0.13	0.12	ON-line LC-GC-FID
15	< 0.2		< 0.2	< 0.2	< 0.2	OFF-line GC-FID
16	0.38	0.19	0.32	0.41	0.37	ON-line LC-GC-FID
17	0.54	0.2	0.51	0.57	0.53	ON-line LC-GC-FID
18	< 1		< 1	< 1	< 1	ON-line LC-GC-FID
19	0.6	0.3	0.6	0.5	0.6	ON-line LC-GC-FID
20	< 0.5		0.41	0.51		
21	0.82	0.34	0.84	0.86	0.77	ON-line LC-GC-FID
22	< 1		< 1	< 1	< 1	ON-line LC-GC-FID
23	< 0.5		< 0.5	< 0.5	< 0.5	Semi-ON line LC-GC-FID
24	0.7	0.2	0.6	0.7	0.8	ON-line LC-GC-FID
25	0.34		0.35	0.34	0.33	ON-line LC-GC-FID
26	0.8	0.16	0.82	0.85	0.8	ON-line LC-GC-FID
27	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID

**Annex 7.** Results as reported by the participants for the **MOAH C25-C35 fraction in IF** (in mg kg<sup>-1</sup>)

LabCode	Result	MU (k=2)	Rep1	Rep2	Rep3	Method
1	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
2	< 0.08		< 0.05	< 0.13	< 0.06	ON-line LC-GC-FID
3	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
4	< 0.1		< 0.1	< 0.1	< 0.1	ON-line LC-GC-FID
5						ON-line LC-GC-FID
6	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
7	< 0.07		< 0.07	< 0.07	< 0.07	ON-line LC-GC-FID
8	0.01					OFF-line GC-FID
9						ON-line LC-GC-FID
10	< 0.05		< 0.05	< 0.05	< 0.05	ON-line LC-GC-FID
11	1.146					
12						ON-line LC-GC-FID
13	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
14	< 0.3		< 0.3	< 0.3	< 0.3	ON-line LC-GC-FID
15	< 0.4		< 0.4	< 0.4	< 0.4	OFF-line GC-FID
16	< 0.15		< 0.15	< 0.15	< 0.15	ON-line LC-GC-FID
17	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
18	< 1		< 1	< 1	< 1	ON-line LC-GC-FID
19	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
20	< 0.5		< 0.5	< 0.5		
21	< 0.3		< 0.3	< 0.3	< 0.3	ON-line LC-GC-FID
22	< 1		< 1	< 1	< 1	ON-line LC-GC-FID
23	< 0.5		< 0.5	< 0.5	< 0.5	Semi-ON line LC-GC-FID
24	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
25	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
26	< 0.2		< 0.2	< 0.2	< 0.2	ON-line LC-GC-FID
27	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID

Annex 8. Results as reported by the participants for the MOAH C16-C25 fraction in IF (in mg kg<sup>-1</sup>)

LabCode	Result	MU (k=2)	Rep1	Rep2	Rep3	Method
1	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
2	< 0.04		< 0.03	< 0.07	< 0.03	ON-line LC-GC-FID
3	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
4	< 0.1		< 0.1	< 0.1	< 0.1	ON-line LC-GC-FID
5						ON-line LC-GC-FID
6	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
7	< 0.07		< 0.07	< 0.07	< 0.07	ON-line LC-GC-FID
8						
9						ON-line LC-GC-FID
10	< 0.05		< 0.05	< 0.05	< 0.05	ON-line LC-GC-FID
11						OFF-line GC-FID
12						ON-line LC-GC-FID
13	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
14	< 0.15		< 0.15	< 0.15	< 0.15	ON-line LC-GC-FID
15	< 0.2		< 0.2	< 0.2	< 0.2	OFF-line GC-FID
16	< 0.15		< 0.15	< 0.15	< 0.15	ON-line LC-GC-FID
17	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
18	< 1		< 1	< 1	< 1	ON-line LC-GC-FID
19	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
20	< 1		< 1	< 1		
21	< 0.3		< 0.3	< 0.3	< 0.3	ON-line LC-GC-FID
22	< 1		< 1	< 1	< 1	ON-line LC-GC-FID
23	< 0.5		< 0.5	< 0.5	< 0.5	Semi-ON line LC-GC-FID
24	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
25	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID
26	< 0.2		< 0.2	< 0.2	< 0.2	ON-line LC-GC-FID
27	< 0.5		< 0.5	< 0.5	< 0.5	ON-line LC-GC-FID

Annex 9. Results as reported by the participants for the MOAH C10-C16 fraction in IF (in mg kg<sup>-1</sup>)

#### **GETTING IN TOUCH WITH THE EU**

#### In person

All over the European Union there are hundreds of Europe Direct information centres. You can find the address of the centre nearest you at: <u>https://europa.eu/european-union/contact\_en</u>

#### On the phone or by email

Europe Direct is a service that answers your questions about the European Union. You can contact this service:

- by freephone: 00 800 6 7 8 9 10 11 (certain operators may charge for these calls),
- at the following standard number: +32 22999696, or
- by electronic mail via: <u>https://europa.eu/european-union/contact\_en</u>

#### FINDING INFORMATION ABOUT THE EU

#### Online

Information about the European Union in all the official languages of the EU is available on the Europa website at: <a href="https://europa.eu/european-union/index\_en">https://europa.eu/european-union/index\_en</a>

#### **EU publications**

You can download or order free and priced EU publications from EU Bookshop at: <u>https://publications.europa.eu/en/publications</u>. Multiple copies of free publications may be obtained by contacting Europe Direct or your local information centre (see <u>https://europa.eu/european-union/contact\_en</u>).

# The European Commission's science and knowledge service

Joint Research Centre

#### **JRC Mission**

As the science and knowledge service of the European Commission, the Joint Research Centre's mission is to support EU policies with independent evidence throughout the whole policy cycle.



EU Science Hub ec.europa.eu/jrc

@EU\_ScienceHub

- **f** EU Science Hub Joint Research Centre
- in EU Science, Research and Innovation

EU Science Hub